287 related articles for article (PubMed ID: 22318617)
1. The state of the art in the development of biosimilars.
McCamish M; Woollett G
Clin Pharmacol Ther; 2012 Mar; 91(3):405-17. PubMed ID: 22318617
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars and the European experience: implications for the United States.
Megerlin F; Lopert R; Taymor K; Trouvin JH
Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
6. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
8. White paper: an outlook on U.S. biosimilar competition.
Bourgoin AF; Nuskey B
Drugs Today (Barc); 2013 Jun; 49(6):399-410. PubMed ID: 23807943
[TBL] [Abstract][Full Text] [Related]
9. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
11. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
12. An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
Minssen T; Kesselheim AS; Darrow JJ
Nat Biotechnol; 2019 Jan; 37(1):21-22. PubMed ID: 30605154
[No Abstract] [Full Text] [Related]
13. Biosimilars: the 'future' of biologic therapy?
Ranjan N; Mahajan VK; Misra M
J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars might not measure up to health plan expectations.
Reinke T
Manag Care; 2012 Oct; 21(10):12-3. PubMed ID: 23156071
[No Abstract] [Full Text] [Related]
15. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Gran-Ruaz S; Mani A; O'Quinn S
Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: current scientific and regulatory considerations.
Chugh PK; Roy V
Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
[TBL] [Abstract][Full Text] [Related]
17. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
18. Patent litigation could make 2017 no 'dancing' matter.
Reinke T
Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
[TBL] [Abstract][Full Text] [Related]
19. Biotech innovators jump on biosimilars bandwagon.
Moran N
Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
[No Abstract] [Full Text] [Related]
20. Insights of biosimilars through SWOT analysis.
Patel MM; Shah PJ; Patel BM
Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
